Registered outcomes17

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 17 of 17

List	Outcome	Time frame	Description
Primary	Number of heavy drinking days, as measured by the Time Line Follow Back	Over 12 weeks	Corroborated with Phosphatidylethanol (PEth) levels
Primary	Time to relapse, as measured by the Time Line Follow Back	Over 12 weeks	Corroborated with PEth levels
Primary	Time to lapse, as measured by the Time Line Follow Back	Over 12 weeks	Corroborated with PEth levels
Primary	Number of days abstinent, as measured by the Time Line Follow Back	Over 12 weeks	Corroborated with PEth levels
Primary	Number of standard drinks per drinking day, as measured by the Time Line Follow Back	12 weeks	Corroborated with PEth levels
Secondary	Self report of adverse events	12 weeks	as reported by patient during weekly medical management sessions facilitated by the treating doctor.
Secondary	Penn Alcohol Craving Scale for alcohol craving	12 weeks	as measured by amount of time spent thinking and craving for alcohol, difficulty in resisting consumption of alcohol if present and hypothetical pleasure associated with consumption of alcohol.
Secondary	DASS21 score for presence and/or severity of anxiety	12 weeks	as measured by cumulative score of anxiety related questions on the Depression, Anxiety Stress Scale-21 (DASS21).
Secondary	DASS21 score for presence and/or severity of depression	12 weeks	as measured by cumulative score for depression related questions
Secondary	Insomnia Severity Index for sleep disturbances	12 weeks	as measured by cumulative score of satisfaction with current sleep patterns and extent to which sleep disturbances interfere and impair with every day activities and daily functioning
Secondary	Blood glucose test for diabetes	12 weeks	as measured by fasting blood glucose levels in blood
Secondary	Liver function tests for clinical markers of liver injury	12 weeks	as measured by levels of liver enzymes, Alanine Transaminase (ALT), Alkaline Phosphatase (ALP) and Aspartate Transaminase (AST) in blood
Secondary	Body Mass Index	12 weeks	as measured by weight in kilograms (kg) and height in metres (m). These two measurements will be combined together to report BMI in kg/m\^2.
Secondary	Number of cigarettes smoked daily, as measured by Time Line Follow Back	12 weeks
Secondary	Self report of daily measures of expectancies, confidence and drinking	12 weeks	as measured using a scale of the likelihood of having a good time and feeling more relaxed if alcohol was consumed.
Other	The moderating effect of the OPRM1 polymorphism in response to naltrexone, as measured by number of heavy drinking days	12 weeks
Other	Cost-effectiveness of topiramate versus naltrexone, as measured by Disability-Adjusted Life Years (DALYs)	12 weeks

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03479086/registered

API reference For AI assistants